Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05406401

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

This study consists of a dose escalation/confirmation phase and an efficacy expansion phase. The dose escalation/confirmation phase is to determine the safety and tolerability and establish a preliminary recommended Phase 2 dose (RP2D) of zilovertamab vedotin when administered in combination with R-CHP in participants with DLBCL who have received no prior treatment for their disease. The efficacy expansion phase is to determine the efficacy of the RP2D of zilovertamab vedotin when administered in combination with R-CHP in participants with DLBCL who have received no prior treatment for their disease.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Lymphoma, Large B-Cell, Diffuse (DLBCL) Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

BC Cancer Victoria-Clinical Trials Unit ( Site 0105), Victoria, British Columbia, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion:

  • Has histologically confirmed diagnosis of DLBCL by prior biopsy
  • Has PET-positive disease verified by blinded independent central review (BICR) at screening, defined as 4-5 on the Lugano response criteria 5-point scale
  • Has received no prior treatment for DLBCL
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 7 days prior to the start of study intervention

Exclusion:

  • Has a history of transformation of indolent disease to DLBCL
  • Has received solid organ transplant at any time
  • Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL)
  • Has clinically significant (ie, active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication
  • Has pericardial effusion or clinically significant pleural effusion
  • Has ongoing Grade >1 peripheral neuropathy
  • Has a demyelinating form of Charcot-Marie-Tooth disease
  • History of a second malignancy unless potentially curative treatment has been completed with no evidence of malignancy for 2 years with the exception of participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous-cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder
  • Has received prior radiotherapy within 28 days of start of study intervention
  • Has ongoing corticosteroid therapy (exceeding 30 mg daily of prednisone equivalent)
  • Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
  • Has received a strong inhibitor or inducer of CYP3A4 (including itraconazole, ketoconazole, posaconazole, or voriconazole) within 7 days prior to the start of study intervention or expected requirement for chronic use of a strong CYP3A4 inhibitor until <30 days after the last dose
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 28 days before the first dose of study intervention
  • Has known active central nervous system (CNS) lymphoma
  • Has an active infection requiring systemic therapy
  • Has a known history of human immunodeficiency virus (HIV) infection
  • Has a known active hepatitis C virus infection
  • Has a known active hepatitis B virus infection

Treatment and study plan

Zilovertamab vedotin

Biological

IV infusion

Other names: MK-2140, VLS-101

Cyclophosphamide

Drug

IV infusion

Other names: CYTOXAN®, NEOSAR®

Doxorubicin

Drug

IV infusion

Other names: ADRIAMYCIN®

Rituximab

Biological

IV infusion

Other names: RITUXAN®

Rituximab Biosimilar

Biological

IV infusion

Other names: TRUXIMA®

Prednisone

Drug

IV or oral administration (per local guidelines)

Prednisolone

Drug

IV or oral administration (per local guidelines)

Primary outcomes

  1. Number of Participants Who Experienced Dose-limiting Toxicities (DLTs) in Cycle 1

    Time frame: Cycle 1 (up to 21 days)

    DLTs will be evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 and are defined as any drug-related adverse event (AE) observed during the DLT evaluation period (e.g. Cycle 1) that results in a change to a given dose or a delay in initiating the next cycle. The number of participants with DLTs in Cycle 1 will be reported.

  2. Number of Participants Who Experienced At Least One AE

    Time frame: Up to approximately 8 months

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experience an AE will be reported.

  3. Number of Participants Who Discontinued Study Treatment Due to an AE

    Time frame: Up to approximately 5.5 months

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

  4. Complete Response Rate (CRR) per Lugano Response Criteria

    Time frame: Up to approximately 60 months

    CRR is defined as the percentage of participants who achieve a Complete Response (CR) per Lugano response criteria [Cheson, B. D., et al 2014] for malignant lymphoma as assessed by the investigator. Assessment includes anatomic imaging with computed tomography (CT) or magnetic resonance imaging (MRI), metabolic imaging with positron emission tomography (PET), and clinical findings including physical examination and bone marrow biopsy results. The percentage of participants with CRR will be reported.

Secondary outcomes

  1. Objective Response Rate (ORR) per Lugano Response Criteria

    Time frame: Up to approximately 60 months

    ORR is defined as the percentage of participants who achieve a CR or PR per Lugano response criteria [Cheson, B. D., et al 2014] for malignant lymphoma as assessed by the investigator. Assessment includes anatomic imaging with CT or MRI, metabolic imaging with PET, and clinical findings including physical examination and bone marrow biopsy results. The percentage of participants with ORR will be reported.

  2. Duration of Response (DOR) per Lugano Response Criteria

    Time frame: Up to approximately 60 months

    For participants who demonstrate a confirmed CR or PR per Lugano response criteria [Cheson, B. D., et al 2014] for malignant lymphoma, DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first. CR and PR assessment includes anatomic imaging with CT or MRI, metabolic imaging with PET, and clinical findings including physical examination and bone marrow biopsy results. DOR as assessed by the investigator will be reported.

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP in Participants With DLBCL (waveLINE)

Acronym: waveLINE-007

Important dates

Study start
2022
Primary completion
2029
Study completion
2029
First posted
Jun 6, 2022
Registry last updated
Oct 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.